Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
States have an important role in ensuring food safety and healthy food practices.
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
Subscribe To Our Newsletter & Stay Updated
